Savannah, Ga., USA - September 6, 2010, Savannah, Ga., USA - Health Discovery Corporation announced that Herbert A. Fritsche joined the company as senior vice president and chief science officer.
Article continues below
Dr. Fritsche served as Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. During his 41 years at M.D. Anderson Cancer Center, Dr. Fritsche has focused his research activities on the development and validation of cancer diagnostics.
Dr. Fritsche has been involved with the commercialization of every serum cancer biomarker product in use in the United States, and many of the new tissue based molecular markers.
Dr. Fritsche has served as President of the Clinical Ligand Assay Society (CLAS) and on various national committees for both the CLAS and the American Association for Clinical Chemistry (AACC).
Dr. Fritsche is a Fellow of the National Academy of Clinical Biochemistry and was awarded the National Award for Contributions in Education by the AACC; the Outstanding Clinical Chemist Award by the Texas Section, AACC; a Dean's Excellence Award from the University of Texas Graduate School of Biomedical Science; a Distinguished Scientist Award from the CLAS; and the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry.
In 2006, Dr. Fritsche was awarded the Morton K. Schwartz AACC Award for Research Contributions in Cancer Diagnostics. In 2009, he was awarded the Carl Jolliff Lifetime Achievement Award for Contributions in Clinical and diagnostic Immunology.
Dr. Fritsche has served on the Expert Panel for Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO), and the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry. In addition, he serves on the Editorial Board of six international scientific journals.
Dr. Fritsche has served as a consultant/advisor to the National Cancer Institute (NCI) and the U.S. Food and Drug Administration (FDA), and many major international diagnostic companies and biotech start-up companies. ■